Navigation Links
Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
Date:6/4/2008

Private offering provides new funding as Arno Therapeutics, Inc. becomes a

publicly reporting company.

FAIRFIELD, N.J., June 4 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc., a biopharmaceutical company focused on developing therapies for the treatment of cancer, announced the successful completion of its merger with Laurier International, Inc., a publicly traded company currently traded under the ticker symbol "LRRI.OB". Arno will continue to trade under the symbol LRRI.OB until such time as it receives a new symbol.

As previously announced on March 5, 2008, Arno, Laurier and Laurier Acquisition, Inc., a wholly-owned subsidiary of Laurier, entered into a merger agreement pursuant to which Laurier Acquisition would merge into Arno, with Arno becoming the wholly-owned subsidiary of Laurier. The merger was completed on June 3, 2008. Immediately thereafter, Arno merged with and into Laurier, and Laurier changed its name to Arno Therapeutics, Inc. In addition, upon the completion of the merger, the officers and directors of the former Arno Therapeutics became the officers and directors of the resulting company.

Prior to the merger, Arno completed an $18 million private financing through the sale of shares of common stock to an investor group comprised of select institutional and qualified investors. Riverbank Capital Securities, Inc., a FINRA member broker dealer, acted as placement agent in connection with the financing.

"We are extremely excited about the successful financing and merger, which leaves us in a strong position to advance our pipeline as rapidly as possible," said Scott Fields, M.D., President and Chief Medical Officer of Arno. "We look forward to moving into Phase II clinical studies with our lead product, AR-67, and to completing IND enabling pre-clinical work for AR-12 and AR-42."

The proceeds from the financing will be used primarily to fund further development of Arno's oncology pipe
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
10. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
11. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... THOUSAND OAKS, Calif. , May 22, ... today announced the Company has commenced termination ... commercialization of brodalumab with AstraZeneca (LON:AZN, STO:AZN ... investigational IL-17 inhibitor, is in development for ... and axial spondyloarthritis.  The decision was based ...
(Date:5/22/2015)... 22, 2015  Effective staffing of key marketing ... and success. Research and consulting ... provide pharmaceutical and biotech marketing managers with metrics ... that are being channeled into marketing operations of ... can utilize this report to benchmark their own ...
(Date:5/22/2015)... Electrophysiologist Kevin Makati, M.D. with St. ... Boston, MA to speak about ... Society conference. These scientific sessions drew more than ... people and technology that propel their specialty forward. ... invasive cardiac operation that combines the expertise of ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3
... patients achieve undetectable HCV RNA levels following 4 weeks of ... and tolerability comparable to placebo administered with Pegasys ... ... VRUS ) announces the preliminary results of the third cohort of a,4-week ...
... achieved SVR 12 with 48-week boceprevir-based ... combination therapy ... arm, KENILWORTH, N.J., Aug. 4 Schering-Plough,Corporation (NYSE: SGP ) ... study of boceprevir, its investigational,oral hepatitis C protease inhibitor. The analysis showed ...
Cached Medicine Technology:Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 2Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 3Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 4Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 5Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 2Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 3Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 4Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 5Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 6Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 7Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 8Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 9
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
(Date:5/22/2015)... May 22, 2015 “It’s like ... SLP, RAC-CT, CHHRP-QT, Vice President of Clinical Operations/Education ... important ‘language’ that impacts how care is coded ... in long term care reimbursement, operations and compliance ... and talent management, launches a new series of ...
(Date:5/22/2015)... 2015 Carnegie Science Center ... a new partnership to develop BodyTech, a dynamic, three-pronged ... initiative includes a new exhibit at the Science Center ... and a new traveling science show, Anatomy Adventure, which ... , Designed to explore a wide range of ...
(Date:5/22/2015)... 22, 2015 Memorial Day weekend is typically ... is offering some tips to help promote safe travel. ... will be 383 traffic fatalities this Memorial Day weekend. Amica ... Highway Traffic Safety Association: , , ... is wearing a seatbelt, whether they’re driving or riding along ...
(Date:5/22/2015)... 2015 Power Systems is proud to announce ... race season. Drobeck is in his second year of racing ... with the Missoula Fire Department in Missoula, MT. He entered ... 2014. During his career, he has had 15 1st Place ... top 10 finishes in all seven of his 2014 races, ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
... Reading a book can satisfy the crucial human need for ... 140 university students who were given 30 minutes to read ... Twilight or the wizard novel Harry Potter and ... of either vampires or wizards. The participants were then ...
... rising levels of cardiovascular disease (CVD) in the Asia Pacific ... the first time- the Society will send an official delegation ... The 18th edition of the APCC meeting will be ... 2011. The ESC deputation will present an educational programme called ...
... Chief of both the Division of Allergy and Inflammation and ... Center (BIDMC), is the recipient of an NIH MERIT ... A Professor of Medicine at Harvard Medical School, Weller received ... Functioning." An acronym for the Method to Extend Research ...
... is regarded as the most thorough way to ... procedure can also be painful. Scientists and engineers ... reduce patient discomfort while also ensuring the accuracy ... of Engineering led by Associate Professor of Mechanical ...
... accepted for publication in The Endocrine Society,s Journal of ... and white children with vitamin D deficiency both had higher ... levels of fat just under their skin and white children ... their internal organs. Studies in adults and children have ...
... The Scripps Research Institute and Tampa,s Moffitt Cancer ... study the formation and progression of prostate cancer. Of ... Scripps Research, with the remaining $138,380 supporting Moffitt Cancer ... Institutes of Health (NIH) will fund research to advance ...
Cached Medicine News:Health News:The European Society of Cardiology organizes educational program in Asia 2Health News:BIDMC's Peter Weller, M.D., receives NIH MERIT Award 2Health News:A less painful colonoscopy 2Health News:A less painful colonoscopy 3Health News:Vitamin D deficiency is associated with different types of obesity in black and white children 2Health News:Scripps Research wins more than $2 million to study prostate cancer 2
... nRBC-Chex for LH is a nucleated red blood ... precision of the Coulter LH 750/LH 755 hematology ... The assay provides for the Coulter LH 750/LH ... packaged in plastic, cap-pierceable vials. nRBC-Chex for LH ...
Indicated to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions, including chronic total coronary occlusions....
... 12 Extend is a three-part differential control assayed ... STKR, J Series, T Series, AcT/AcT diff/AcT diff2, ... 1500, 1600, 1700, and 1800; ABX Micros 60; ... Extend has an open-vial stability of 30 days ...
... 5-part differential control that controls all parameters, ... LH 750/LH 755, MAXM and HmX instruments. ... values for all three levels. White blood ... are within clinically significant ranges. This unique ...
Medicine Products: